Article Sidebar

pdf
Date Published: 09/09/2023
Abstract Views: 258
Views pdf: 173
DOI: https://doi.org/10.51298/vmj.v529i2.6475
Issue
Vol. 529 No. 2 (2023)
Section
Các bài báo
How to Cite
Phạm, T. A., & Nguyễn, T. P. A. (2023). EFFICACY OF CORTICOSTEROID FOR PROPHYLAXIS OF PACLITAXEL HYPERSENSITIVITY REACTIONS. Vietnam Medical Journal, 529(2). https://doi.org/10.51298/vmj.v529i2.6475

EFFICACY OF CORTICOSTEROID FOR PROPHYLAXIS OF PACLITAXEL HYPERSENSITIVITY REACTIONS

Tuấn Anh Phạm1,, Thị Phương Anh Nguyễn1
1 K Hospital

Main Article Content

Abstract

Objectives: To eValuate the efficacy of corticosteroids in preVenting hypersensitiVity reactions of paclitaxel in adjuVant chemotherapy for breast cancer. Patients and method: A study of 100 non- metastatic breast cancer patients who were treated with Paclitaxel from Mar 2021 to Dec 2022 at K Hospital. Results: The youngest patient was 27 years-old, the oldest patient was 60 years old. The mean age was 49. InVasiVe ductal carcinoma accounted for 82% and lobular carcinoma was 18%. The most patient was Her2 positiVe group, accounting for 35%. The most patient in the study was in stage II, accounting for 75%. Grade 1,2 hypersensitiVity reactions was 7.5-12%. Grade 3 less than 5% and anaphylaxis less than 1%. The most common


 


                                                                                                                                                                                  


                                                                                                                                                                                  


 


hypersensitiVity symptoms were hot flushes (21.5- 22%), chest pain (21-21.5%), dyspnea (18.5-19.5%),


tachycardia (18-19%) and hypotension (17-17.5%). The difference was not statistically significant between two groups.

Article Details

Keywords

breast cancer, paclitaxel, Prophylaxis for hypersensitiVity reaction

References

1. Kintzel PE. Prophylaxis for paclitaxel hypersensitiVity reactions. Ann Pharmacother. 2001; 35:1114–17. doi: 10.1345/aph.10287.
2. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitiVity reactions: experience of the Gyne- cologic Oncology Program of the CleVeland Clinic Cancer Centre. J Clin Oncol 2000;18:102–5.
3. Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intraVenous premedication with dexamethasone preVents hypersensitiVity reactions to paclitaxel. Ann Oncol. 1996; 7:978–
79. doi: 10.1093/oxfordjournals.annonc.a010806.
4. Hua XM, Liu FL, Ren XW, Duan GX, Li ZJ, Zhang CJ, Yang YJ, Zhang GX. A study of steroid premedication for hypersensitiVity reaction and reinfusion in taxane family regimen. J Pract Oncol. 2004; 18:38–40.
5. Chen Y, Qi HX. A comparison of two premedication protocols for hypersensitiVity reactions to paclitaxel. J Chifeng UniV. 2013; 29:108–09.
6. Sui M, Chen F, Chen Z, Fan W. Glucocorticoids



interfere with therapeutic efficacy of paclitaxel against human breast and oVarian xenograft tumors. Int J Cancer. 2006; 119:712– 17. doi: 10.1002/ijc.21743.
7. Prieto García A, Pineda de la Losa F. Immunoglobulin E-mediated seVere anaphylaxis to paclitaxel. J InVestig Allergol Clin Immunol. 2010; 20:170–71.

8. Raisch DW, Campbell W, Garg V, Qureshi ZP, Bookstaver PB, Norris LB, Bennett CL. Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011; 10:521–28. doi: 10.1517/ 14740338.2011.582865